Home/Filings/4/A/0001562180-25-001915
4/A//SEC Filing

Leonard Frank X 4/A

Accession 0001562180-25-001915

CIK 0001645113other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 9:26 PM ET

Size

14.8 KB

Accession

0001562180-25-001915

Insider Transaction Report

Form 4/AAmended
Period: 2025-02-27
Leonard Frank X
EVP, Pres., Novocure Oncology
Transactions
  • Sale

    Ordinary Shares

    2025-02-27$19.92/sh10,277$204,737150,959 total
  • Sale

    Ordinary Shares

    2025-02-27$20.55/sh1,989$40,872148,970 total
  • Sale

    Ordinary Shares

    2025-02-28$18.28/sh2,770$50,648146,200 total
Footnotes (4)
  • [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  • [F2]On February 27, 2025, the reporting person sold 10,277 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]On February 27, 2025, the reporting person sold 1,989 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]On February 28, 2025, the reporting person sold 2,770 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Issuer

NovoCure Ltd

CIK 0001645113

Entity typeother

Related Parties

1
  • filerCIK 0001822879

Filing Metadata

Form type
4/A
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 9:26 PM ET
Size
14.8 KB